Abstract
Tubulointerstitial fibrosis is the final common pathway leading to end stage chronic kidney disease (CKD), ultimately with renal replacement therapy. So far, there is no approved antifibrotic therapy for this situation. Myofibroblasts, the effector cells of renal fibrosis, contribute to the establishment and progression of fibrogenesis. Myofibroblasts have a particularly high expression o…